Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood glucose, while also decreasing risk of kidney disea...

Full description

Bibliographic Details
Main Authors: Viktor Rotbain Curovic, Morten B. Houlind, Tine W. Hansen, Jesper Eugen-Olsen, Jens Christian Laursen, Mie K. Eickhoff, Frederik Persson, Peter Rossing
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
type 1 diabetes
inflammation
suPAR
soluble urokinase receptor
clinical trial
randomized controlled trial
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.799915/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.799915/full

Similar Items